Memphasys Limited (MEM.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 | 164.76 Thousand AUD | 25.98% |
| 2023 | 130.78 Thousand AUD | 50.19% |
| 2022 | 87.08 Thousand AUD | -26.69% |
| 2021 | 118.79 Thousand AUD | 263.55% |
| 2020 | 32.67 Thousand AUD | 102.96% |
| 2019 | -1.1 Million AUD | -86.13% |
| 2018 | -592.73 Thousand AUD | 0.0% |
| 2017 | - AUD | 0.0% |
| 2016 | - AUD | -100.0% |
| 2015 | 12.37 Thousand AUD | -95.88% |
| 2014 | 300.23 Thousand AUD | -25.01% |
| 2013 | 400.38 Thousand AUD | 8.06% |
| 2012 | 370.52 Thousand AUD | -13.17% |
| 2011 | 426.74 Thousand AUD | 10.25% |
| 2010 | 387.06 Thousand AUD | 32.22% |
| 2009 | 292.73 Thousand AUD | -21.83% |
| 2008 | 374.49 Thousand AUD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 FY | 164.76 Thousand AUD | 25.98% |
| 2024 Q2 | 141.03 Thousand AUD | 0.0% |
| 2024 Q4 | 164.76 Thousand AUD | 0.0% |
| 2023 Q2 | 50.38 Thousand AUD | 0.0% |
| 2023 Q4 | 130.78 Thousand AUD | 0.0% |
| 2023 FY | 130.78 Thousand AUD | 50.19% |
| 2022 Q2 | 94.85 Thousand AUD | 0.0% |
| 2022 Q4 | 87.08 Thousand AUD | 0.0% |
| 2022 FY | 87.08 Thousand AUD | -26.69% |
| 2021 FY | 118.79 Thousand AUD | 263.55% |
| 2021 Q4 | 118.79 Thousand AUD | 0.0% |
| 2021 Q2 | 99.82 Thousand AUD | 0.0% |
| 2020 Q2 | 3745.00 AUD | 0.0% |
| 2020 FY | 32.67 Thousand AUD | 102.96% |
| 2020 Q4 | 32.67 Thousand AUD | 0.0% |
| 2019 FY | -1.1 Million AUD | -86.13% |
| 2019 Q4 | -1.1 Million AUD | 0.0% |
| 2019 Q2 | - AUD | 0.0% |
| 2018 FY | -592.73 Thousand AUD | 0.0% |
| 2018 Q4 | - AUD | 0.0% |
| 2018 Q2 | - AUD | 0.0% |
| 2017 Q4 | - AUD | 0.0% |
| 2017 FY | - AUD | 0.0% |
| 2017 Q2 | - AUD | 0.0% |
| 2016 Q2 | 5216.00 AUD | 0.0% |
| 2016 FY | - AUD | -100.0% |
| 2016 Q4 | - AUD | 0.0% |
| 2015 Q4 | 12.37 Thousand AUD | 0.0% |
| 2015 Q2 | 336.13 Thousand AUD | 0.0% |
| 2015 FY | 12.37 Thousand AUD | -95.88% |
| 2014 Q2 | 400.62 Thousand AUD | 0.0% |
| 2014 FY | 300.23 Thousand AUD | -25.01% |
| 2014 Q4 | 300.23 Thousand AUD | 0.0% |
| 2014 Q3 | 300.23 Thousand AUD | -25.06% |
| 2014 Q1 | 400.62 Thousand AUD | 0.06% |
| 2013 Q2 | 409.55 Thousand AUD | 0.0% |
| 2013 Q1 | 409.55 Thousand AUD | 10.53% |
| 2013 Q4 | 400.38 Thousand AUD | 0.0% |
| 2013 FY | 400.38 Thousand AUD | 8.06% |
| 2013 Q3 | 400.38 Thousand AUD | -2.24% |
| 2012 FY | 370.52 Thousand AUD | -13.17% |
| 2012 Q4 | 370.52 Thousand AUD | 0.0% |
| 2011 Q4 | 426.74 Thousand AUD | 0.0% |
| 2011 FY | 426.74 Thousand AUD | 10.25% |
| 2010 FY | 387.06 Thousand AUD | 32.22% |
| 2010 Q4 | 387.06 Thousand AUD | 0.0% |
| 2009 Q4 | 292.73 Thousand AUD | 0.0% |
| 2009 FY | 292.73 Thousand AUD | -21.83% |
| 2008 Q4 | 374.49 Thousand AUD | 0.0% |
| 2008 FY | 374.49 Thousand AUD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 1.4 Million AUD | 88.241% |
| Anatara Lifesciences Ltd | -671.09 Thousand AUD | 124.551% |
| Zelira Therapeutics Limited | 1.25 Million AUD | 86.843% |
| Biome Australia Limited | 1.88 Million AUD | 91.276% |
| Patrys Limited | - AUD | -Infinity% |
| Orthocell Limited | 1.17 Million AUD | 85.997% |
| Imugene Limited | - AUD | -Infinity% |
| Noxopharm Limited | -2.35 Million AUD | 106.984% |
| PYC Therapeutics Limited | -17.99 Million AUD | 100.916% |
| Chimeric Therapeutics Limited | - AUD | -Infinity% |
| Prescient Therapeutics Limited | - AUD | -Infinity% |
| Proteomics International Laboratories Limited | - AUD | -Infinity% |
| Cynata Therapeutics Limited | 108.2 Thousand AUD | -52.269% |
| CSL Limited | 8.93 Billion AUD | 99.998% |
| Arovella Therapeutics Limited | - AUD | -Infinity% |
| Bio-Gene Technology Limited | - AUD | -Infinity% |
| Clinuvel Pharmaceuticals Limited | 10.62 Million AUD | 98.45% |
| Starpharma Holdings Limited | 2.4 Million AUD | 93.158% |
| Nanollose Limited | - AUD | -Infinity% |
| Invex Therapeutics Ltd | -94.98 Thousand AUD | 273.464% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | - AUD | -Infinity% |
| Botanix Pharmaceuticals Limited | 1.2 Million AUD | 86.376% |
| Island Pharmaceuticals Limited | -877.24 Thousand AUD | 118.782% |
| Race Oncology Limited | 16.4 Thousand AUD | -904.579% |
| Nyrada Inc. | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 17.31 Million AUD | 99.048% |
| Dimerix Limited | - AUD | -Infinity% |
| PharmAust Limited | - AUD | -Infinity% |
| Immutep Limited | 2.00 AUD | -8237950.0% |
| Clarity Pharmaceuticals Ltd | - AUD | -Infinity% |
| Alterity Therapeutics Limited | 1.00 AUD | -16476000.0% |
| BTC Health Limited | - AUD | -Infinity% |
| Acrux Limited | 147 Thousand AUD | -12.082% |
| Neuren Pharmaceuticals Limited | - AUD | -Infinity% |
| Biotron Limited | - AUD | -Infinity% |
| Tissue Repair Ltd | 214.72 Thousand AUD | 23.268% |
| AdAlta Limited | -1.67 Million AUD | 109.81% |
| Radiopharm Theranostics Limited | -987.41 Thousand AUD | 116.686% |
| Hexima Limited | - AUD | -Infinity% |
| AnteoTech Limited | 221.85 Thousand AUD | 25.735% |
| Paradigm Biopharmaceuticals Limited | - AUD | -Infinity% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Avecho Biotechnology Limited | 97.11 Thousand AUD | -69.652% |
| Actinogen Medical Limited | 108.82 Thousand AUD | -51.394% |
| Immuron Limited | 1.58 Million AUD | 89.602% |
| Argenica Therapeutics Limited | - AUD | -Infinity% |